兴齐眼药 reported revenue of ¥1.40B for the period ended 2026-06-30, +20.5% year on year. Net income was ¥0.43B, a 30.7% net margin on a 82.3% gross margin. The largest revenue line is 滴眼剂 at 80% of the total. Free cash flow for the period was ¥0.15B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.40B | +20.5% |
| Gross profit | ¥1.15B | — |
| Operating income | ¥0.50B | — |
| Net income | ¥0.43B | +28.5% |
| Gross margin | 82.3% | Net margin 30.7% |
| Revenue Q/Q | +5.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 滴眼剂 | ¥1.12B | 80.1% |
| 凝胶剂/眼膏剂 | ¥0.20B | 14.2% |
| 其他主营业务 | ¥0.08B | 5.5% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.25B | 17.7% |
| R&D | ¥0.16B | 11.5% |
| SG&A | ¥0.49B | 35.3% |
| Tax & other | ¥0.06B | 4.6% |
| Item | Amount |
|---|---|
| Total assets | ¥2.74B |
| Total liabilities | ¥0.58B |
| Shareholders' equity | ¥2.16B |
| Equity / assets | 78.8% |
| Operating cash flow | ¥0.18B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.15B |
| Cash conversion (OCF / net income) | 91% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中旗股份 ・ 容大感光 ・ 开润股份 ・ 会畅科技 ・ 数字认证 ・ 贝斯特 ・ 晨曦航空 ・ 英飞特 ・ 赛托生物 ・ 海辰药业 ・ 奥联电子 ・ 美联新材
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies